Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 1
2006 2
2007 1
2008 2
2012 1
2018 1
2020 1
2021 1
2022 4
2023 2

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial.
van der Heijde D, Baraliakos X, Sieper J, Deodhar A, Inman RD, Kameda H, Zeng X, Sui Y, Bu X, Pangan AL, Wung P, Song IH. van der Heijde D, et al. Among authors: wung p. Ann Rheum Dis. 2022 Nov;81(11):1515-1523. doi: 10.1136/ard-2022-222608. Epub 2022 Jul 4. Ann Rheum Dis. 2022. PMID: 35788492 Free PMC article. Clinical Trial.
Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Deodhar A, Van den Bosch F, Poddubnyy D, Maksymowych WP, van der Heijde D, Kim TH, Kishimoto M, Blanco R, Duan Y, Li Y, Pangan AL, Wung P, Song IH. Deodhar A, et al. Among authors: wung p. Lancet. 2022 Jul 30;400(10349):369-379. doi: 10.1016/S0140-6736(22)01212-0. Lancet. 2022. PMID: 35908570 Clinical Trial.
Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension.
van der Heijde D, Deodhar A, Maksymowych WP, Sieper J, Van den Bosch F, Kim TH, Kishimoto M, Östör AJ, Combe B, Sui Y, Duan Y, Wung PK, Song IH. van der Heijde D, et al. Among authors: wung pk. RMD Open. 2022 Jul;8(2):e002280. doi: 10.1136/rmdopen-2022-002280. RMD Open. 2022. PMID: 35896281 Free PMC article. Clinical Trial.
"Still" ill?
Wung PK, Pipeling MR, Wigley FM. Wung PK, et al. Am J Med. 2008 Jun;121(6):491-3. doi: 10.1016/j.amjmed.2008.02.010. Am J Med. 2008. PMID: 18501228 No abstract available.
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial.
Lescure FX, Honda H, Fowler RA, Lazar JS, Shi G, Wung P, Patel N, Hagino O; Sarilumab COVID-19 Global Study Group. Lescure FX, et al. Among authors: wung p. Lancet Respir Med. 2021 May;9(5):522-532. doi: 10.1016/S2213-2600(21)00099-0. Epub 2021 Mar 4. Lancet Respir Med. 2021. PMID: 33676590 Free PMC article. Clinical Trial.
Therapeutics of Wegener's granulomatosis.
Wung PK, Stone JH. Wung PK, et al. Nat Clin Pract Rheumatol. 2006 Apr;2(4):192-200. doi: 10.1038/ncprheum0139. Nat Clin Pract Rheumatol. 2006. PMID: 16932685 Review.
An atypical complication of atypical pneumonia.
Antonarakis ES, Wung PK, Durand DJ, Leyngold I, Meyerson DA. Antonarakis ES, et al. Among authors: wung pk. Am J Med. 2006 Oct;119(10):824-7. doi: 10.1016/j.amjmed.2006.08.011. Am J Med. 2006. PMID: 17000209 No abstract available.
16 results